Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01454401
Other study ID # H-4-2010-090
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2010
Est. completion date January 2013

Study information

Verified date March 2023
Source Reapplix
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LeucoPatch™ study goal is to investigate whether the fully autologous growth factor-containing dressing LeucoPatch™ has a positive effect on healing rates of diabetic foot ulcers. The study seeks to gather data for comparison with previous data from similar wounds (historical controls). By subgrouping of the treated wounds (similar to the historical controls used) an assessment of which of the patient and wound-related factors that might indicate a beneficial effect of LeucoPatch™ is sought.


Description:

Summary: Treatment Study The goal of the LeucoPatch ™ study is to investigate the effect of LeucoPatch ™ in diabetic foot ulcer. LeucoPatch ™ is a biologically active dressings which are made solely by the patient's own blood (autologous). It is produced in the CE (European Conformity) marked LeucoPatch™ Device and contains no additives. In this treatment study up to 75 typical diabetic patients with foot ulcers are included. These wounds are typically chronic and lead to reduced quality of life and ability to work, and extensive treatment costs. Furthermore, these wounds often lead to amputations.The study is a multicenter study in which up to 10 wound clinics are expected to be involved. The primary endpoint is time to complete healing, the secondary endpoint is change in wound size.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 2013
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Type I or Type II Diabetes - Age of wounds > 6 weeks - Wound area <10 cm2 - Wounds: Texas degree = type IIa - Perfusion status: toe pressure> 30 mmHg, or transcutaneous oxygen measurement (TcPO2)> 30 mmHg on the foot (measured within the last 3 months) or palpable foot pulse (equivalent to> 60 mmHg) - Diabetes control: HbA1c <12% - Adequate off-loading (Walker, therapy sandals etc.) - The patient can adhere to the treatment protocol and is expected to conclude the study - Written informed consent Exclusion Criteria: - Non-Danish or Swedish speaking - Dementia - Pregnant or nursing women - The patient cannot tolerate blood donation - Hemoglobin : < 6,5 mmol/l or 105 g/l - Haemophilia, Sickle cell anemia, severe thrombocytopenia, and leukemia or blood dyscrasias. - Patient on dialysis - Clinical signs of infection - including osteomyelitis (probe to bone). - Necrosis of the wound - 40% change (+/-) in ulcer area in a 2-week run-in period with optimal therapy. - Blood vessel reconstruction within the last 4 weeks. - Participation in other clinical wound healing studies in the last 30 days. - Failure to comply with study protocol in the 2-week run-in period.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
LeucoPatch treatment
weekly

Locations

Country Name City State
Denmark Knowledge Center for woundhealing, Bispebjerg Hospital Copenhagen
Denmark Steno Diabetes Center Gentofte
Denmark Herlev Hospital, Orthopaedic Surgery Infirmary, Wound Clinic Herlev
Denmark Vascular Center, Wound Clinic Kolding Hospital Kolding
Denmark University center for woundhealing, Odense Hospital Odense
Sweden Ängelholm Hospital, Dept. of Medicine, Diabetic Foot Ulcer Clinic Ängelholm
Sweden Skane University Hospital, Dept. of Endocrinology, Diabetes Foot Ulcer Clinic Lund

Sponsors (1)

Lead Sponsor Collaborator
Reapplix

Countries where clinical trial is conducted

Denmark,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ulcer Healing Within 20 Weeks Number of the patients achieved complete epithelialization at 20 weeks in the ITT population and in the PP population. 20 weeks
Secondary Ulcer Healing Within 12 Weeks. Number of the patients achieved complete epithelialisation at 12 weeks (ITT population) and the percentage respectively in the PP population 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02652754 - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers Phase 1
Completed NCT01070433 - A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers Phase 2
Completed NCT00971048 - Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds N/A
Terminated NCT00762138 - The AutoloGel™ Post-Market Surveillance (TAPS) Program N/A
Completed NCT00578604 - Non-Invasive Assessment of Wound Healing With Optical Methods N/A
Completed NCT05417425 - Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers Phase 1
Completed NCT02631512 - Evaluation of Woulgan in Diabetic Foot Ulcer Phase 4
Terminated NCT01816633 - Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers N/A
Completed NCT02222376 - Effect of Topic Pirfenidone in Diabetic Ulcers Phase 3
Completed NCT01221207 - Instant Total Contact Cast to Heal Diabetic Foot Ulcers N/A
Completed NCT01291160 - Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers Phase 2/Phase 3
Withdrawn NCT01105884 - Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers N/A
Completed NCT00536744 - Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers Phase 3
Terminated NCT00316537 - Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers Phase 1/Phase 2
Completed NCT00013299 - Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3 Phase 2
Completed NCT00013286 - A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk Phase 2
Terminated NCT02667327 - A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Phase 3
Not yet recruiting NCT00916292 - Safety Study of Topical Human FGF-1 for Wound Healing Phase 1
Completed NCT01154374 - A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot) Phase 2
Not yet recruiting NCT02672280 - Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects Phase 1/Phase 2